alexa Use of Subcutaneous Methotrexate for the Treatment of Moderate-to-Severe Psoriasis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

World Conference on Clinical and Medical Case Reports

Perth, Australia
Use of Subcutaneous Methotrexate for the Treatment of Moderate-to-Severe Psoriasis

Methotrexate is an aminopterin derivative that acts via diverse and complex mechanisms to produce anti-proliferative, anti-inflammatory and immunosuppressive effects. As a folic acid antagonist, methotrexate inhibits purine and pyrimidine synthesis, resulting in antineoplastic activity at high dose levels. The anti-inflammatory activity of methotrexate, which is mediated by increased adenosine release, is considered to be most important for its clinical effect on psoriasis .In addition, the immune modulatory properties of methotrexate such as suppression of T-cell activation and altered expression of adhesion molecules are thought to be relevant.

Citation: Ruiz-Villaverde R, Sanchez-Cano D, Garrido-Colmenero C, Pablo, Fernandez-Crehuet (2015) Multiorgan Experience with Subcutaneous Methotrexate for the Treatment of Moderate-to-Severe Psoriasis. J Clin Case Rep

 

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top